1. Hepatitis C treatment outcomes using interferon- and ribavirin-based therapy in Kigali, Rwanda.
- Author
-
Riedel DJ, Taylor S, Simango R, Kiromera A, Sebeza J, Baribwira C, and Musabeyezu E
- Subjects
- Adult, Aged, Antiviral Agents pharmacology, Drug Therapy, Combination, Genotype, Hepacivirus genetics, Hepatitis C virology, Hospitals, Humans, Interferons pharmacology, Middle Aged, Ribavirin pharmacology, Rwanda, Treatment Outcome, Viral Load, Antiviral Agents therapeutic use, Hepacivirus drug effects, Hepatitis C drug therapy, Interferons therapeutic use, Ribavirin therapeutic use
- Abstract
Background: Hepatitis C virus (HCV) treatment data in sub-Saharan Africa are limited. This study was to determine HCV sustained virologic response(SVR) at 24 weeks in patients undergoing HCV therapy in Kigali, Rwanda., Methods: The paper presents data for all patients treated for HCV with ribavirin/interferon at King Faisal Hospital in Kigali, Rwanda, from 1 January 2007 to 31 December 2014., Results and Conclusions: There were 69 evaluable patients. HCV genotype 4(61%, 42/69) predominated. 24-week SVR was 70%(26/37) by per-protocol and 32%(26/69) by intention-to-treat analysis. HCV treatment in Rwanda is feasible. SVR with interferon/ribavirin was acceptable in the per-protocol analysis. Transition to newer direct acting antivirals is urgently needed in Rwanda and sub-Saharan Africa more generally to improve treatment outcomes., (© The Author 2016. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2016
- Full Text
- View/download PDF